Product Description
Product Name |
Retatrutide |
CAS NO. |
2381089-83-2 |
Other name |
LY3437943 GIPR/GP-1R |
Appearance |
White freeze dry Powder |
Purity |
99.88%min. HPLC |
Application |
Drug peptides |
Shelf Life |
24Months |
Storage |
Store at a temperature of 2-8 oC, protected from light |
Retatrutide is a groundbreaking investigational single molecule, meticulously designed to activate the body's receptors for three vital hormones - glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GP-1), setting new standards in biochemical advancements. Currently under rigorous investigation, Retatrutide shows immense promise in revolutionizing obesity treatment, poised to redefine industry standards.
How is Retatrutide distinct from Semagluti and Trizepatide?
Mechanism:
1. Semaglutid operates as a glucagon-like peptide-1 (GP-1) hormone agonist, offering targeted action and precision.
2. Tirezepatide functions as a dual (GP-1 & GIP) hormone agonist, enhancing its effectiveness with combined pathways.
3. Retatrutide stands out with its triple action (GP-1, GIP, & Glucagon) hormone agonist mechanism, ensuring comprehensive and unparalleled benefits.
Weight Loss in Clinical Trials:
1. Semaglutid demonstrated a remarkable 6-12% body weight reduction over 28 weeks, showcasing its efficacy.
2. Tirezepatide achieved a significant 15-20% body weight reduction over 72 weeks, underlining its potent capabilities and transformative impact.
3. Retatrutide excelled with an impressive 25% body weight reduction in just 48 weeks, cementing its potential as a game-changer in weight loss solutions.